UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT


 Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934


        Date of Report (Date of earliest event reported) April 18, 2003


                    BioDelivery Sciences International, Inc.
         ---------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


        Delaware                      0-28931                   35-2089858
----------------------------  ------------------------    ---------------------
(State or other jurisdiction   (Commission File Number)       (IRS Employer
    of incorporation)                                      Identification No.)


        UMDNJ Medical School
  185 South Orange Avenue, Bldg #4
         Newark, New Jersey                                   07103
  ----------------------------------                  -----------------------
(Address of principal executive offices)                    (Zip Code)


Registrant's telephone number, including area code  (973) 972-0015
                                                  ------------------


                                 Not Applicable
                             -----------------------
          (Former name or former address, if changed since last report)



<PAGE>



Items 4 and 9. Change in  Registrant's  Certifying  Accountants;  Regulation  FD
               Disclosure.

On April 18, 2003,  BioDelivery  Sciences  International,  Inc. (the "Company"),
with the  approval  of the  Audit  Committee  of the Board of  Directors  of the
Company (the "Audit  Committee") and the full Board of Directors of the Company,
dismissed its  independent  accountants,  Grant Thornton LLP ("GT").  During the
years  ended  December  31, 2002 and 2001,  and the  subsequent  interim  period
through April 18, 2003 (the date of GT's dismissal as the Company's  independent
accountants),  GT acted as the  independent  accountants for the Company and its
subsidiary, Bioral Nutrient Delivery, LLC, and, during such period there were no
disagreements  with GT on any matters of  accounting  principles  or  practices,
financial  statement   disclosure,   or  auditing  scope  or  procedure,   which
disagreements,  if not resolved to the  satisfaction of GT, would have caused GT
to make a reference to the subject  matter of the  disagreements  in  connection
with its reports in the financial statements for such years.

The  independent  accountant's  report  of  GT  on  the  Company's  consolidated
financial statements for the years ended December 31, 2002 and 2001 contained no
adverse  opinion or  disclaimer of opinion and were not qualified or modified as
to uncertainty, audit scope or accounting principles.

GT has  advised  the  Audit  Committee  and  management  that it noted a lack of
segregation  of  accounting  and financial  reporting  duties as a result of the
Company's  small size,  which  condition GT considered  to be  reportable  under
standards established by the American Institute of Certified Public Accountants.
The Company  believes this matter is not reportable  under Regulation S-B since,
among  other  factors,  the  noted  issue  did not  preclude  the  Company  from
developing    reliable   financial    statements   as   contemplated   by   Item
304(a)(1)(iv)(B)(1)  of Regulation  S-B. The Company is  voluntarily  making the
disclosure  contained in this paragraph,  however,  as an  accommodation  to its
former  independent  accountants.  The  Company  has taken GT's  notation  under
advisement but believes its internal  accounting controls are in compliance with
applicable  accounting  standards,  rules  and  regulations.  The  Company  will
continue to monitor and assess the costs and benefits of additional  staffing in
the  accounting  area  in  conjunction  with  its  newly  appointed  independent
accountants.

The Company has provided a copy of this  disclosure  to its former  accountants,
and the Company requested that the former accountants furnish the Company with a
letter addressed to the Securities and Exchange  Commission stating whether they
agree with the statements made by the Company. A copy of that letter is attached
hereto as Exhibit 16.1.

On April 18, 2003,  with the approval of the Audit  Committee and the full Board
of  Directors  of the  Company,  the firm of Aidman,  Piser & Company,  P.A. was
appointed as the Company's independent accountants.


Item 7. Financial Statements and Exhibits.

Set forth below is a list of Exhibits included as part of this Current Report.

Exhibit No.                Description
-----------                -----------

   16.1       Letter of Grant Thornton LLP, dated April 25, 2003.



<PAGE>



                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant has caused this report to be signed on its behalf by the  undersigned
hereunto duly authorized.


April 25, 2003        BIODELIVERY SCIENCES INTERNATIONAL, INC.



                      By: /s/ Francis E. O'Donnell, Jr.
                          ----------------------------------
                          Name:  Francis E. O'Donnell, Jr.
                          Title: Chairman, President and Chief Executive Officer







Exhibit 16.1


                       [Letterhead of Grant Thornton LLP]


April 25, 2003

Securities and Exchange Commission
Washington, D.C. 20549

RE: BioDelivery Sciences International, Inc.
File No. 0-28931

Dear Sir or Madam:

We have read Item 4 of the Form 8-K of BioDelivery Sciences International, Inc.,
dated  April  18,  2003,  and  agree  with the  statements  concerning  our Firm
contained therein.

Very truly yours,

/s/ Grant Thornton LLP